Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer

5 mg tablets to be administered by mouth at dose selected from safety run-in phase (Ruxolitinib 15 mg twice daily (BID))

5 mg matching placebo tablets to be administered by mouth

500 mg/m\^2 administered as an intravenous infusion over 10 minutes

75 mg/m\^2 infused over 2 hours beginning 30 ± 5 minutes after the end of the pemetrexed infusion